{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:38Z","timestamp":1791632258185,"version":"4.3.4"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00011-025-02126-0","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:21:20Z","timestamp":1762424480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systemic sclerosis, main culprits and involved signaling pathways"],"prefix":"10.1007","volume":"74","author":[{"given":"Omid","family":"Sadatpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Azizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"kavosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vodjgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"10103","key":"2126_CR1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet"},{"issue":"10373","key":"2126_CR2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic sclerosis. Lancet. 2023;401(10373):304\u201318.","journal-title":"Lancet"},{"key":"2126_CR3","volume-title":"StatPearls","author":"R Adigun","year":"2024","unstructured":"Adigun R, Goyal A, Hariz A. Systemic Sclerosis. In: StatPearls. Treasure Island: StatPearls Publishing LLC; 2024."},{"issue":"6","key":"2126_CR4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/BOR.0000000000000755","volume":"32","author":"K Morrisroe","year":"2020","unstructured":"Morrisroe K, Nikpour M. Cancer and scleroderma: recent insights. Curr Opin Rheumatol. 2020;32(6):479\u201387.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"2126_CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304\u201320.","journal-title":"Lancet Respir Med"},{"key":"2126_CR6","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore Y, et al. Systemic sclerosis. Nat Rev Dis Prim. 2015;1:15002.","journal-title":"Nat Rev Dis Prim"},{"issue":"5","key":"2126_CR7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2021.10.065","volume":"87","author":"R Jerjen","year":"2022","unstructured":"Jerjen R, et al. Systemic sclerosis in adults. Part I: clinical features and pathogenesis. J Am Acad Dermatol. 2022;87(5):937\u201354.","journal-title":"J Am Acad Dermatol"},{"key":"2126_CR8","unstructured":"Adigun R, Goyal A, Hariz A. Systemic sclerosis. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430875\/. 2022."},{"issue":"5","key":"2126_CR9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.17219\/acem\/64334","volume":"26","author":"EJ Kucharz","year":"2017","unstructured":"Kucharz EJ, Kope\u0107-M\u0119drek M. Systemic sclerosis sine scleroderma. Adv Clin Exp Med. 2017;26(5):875\u201380.","journal-title":"Adv Clin Exp Med"},{"issue":"5","key":"2126_CR10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2021.10.066","volume":"87","author":"R Jerjen","year":"2022","unstructured":"Jerjen R, et al. Systemic sclerosis in adults. Part II: management and therapeutics. J Am Acad Dermatol. 2022;87(5):957\u201378.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2126_CR11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/BOR.0000000000000959","volume":"35","author":"Y Kawaguchi","year":"2023","unstructured":"Kawaguchi Y, Kuwana M. Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis. Curr Opin Rheumatol. 2023;35(6):309\u201316.","journal-title":"Curr Opin Rheumatol"},{"key":"2126_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814385","author":"E Patnaik","year":"2023","unstructured":"Patnaik E, et al. Endothelial dysfunction in systemic sclerosis. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241814385.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2126_CR13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/kjm2.12505","volume":"38","author":"AH Rosendahl","year":"2022","unstructured":"Rosendahl AH, Sch\u00f6nborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022;38(3):187\u201395.","journal-title":"Kaohsiung J Med Sci"},{"issue":"2","key":"2126_CR14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/rheumatology\/keac410","volume":"62","author":"Y Al-Adwi","year":"2023","unstructured":"Al-Adwi Y, et al. Macrophages as determinants and regulators of fibrosis in systemic sclerosis. Rheumatology. 2023;62(2):535\u201345.","journal-title":"Rheumatology"},{"issue":"7","key":"2126_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-019-0831-z","volume":"21","author":"DM Toledo","year":"2019","unstructured":"Toledo DM, Pioli PA. Macrophages in systemic sclerosis: novel insights and therapeutic implications. Curr Rheumatol Rep. 2019;21(7):31.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"2126_CR16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/BOR.0000000000000827","volume":"33","author":"JR Arron","year":"2021","unstructured":"Arron JR. Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment. Curr Opin Rheumatol. 2021;33(6):480\u20135.","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"2126_CR17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","volume":"15","author":"M Cutolo","year":"2019","unstructured":"Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019;15(7):753\u201364.","journal-title":"Expert Rev Clin Immunol"},{"key":"2126_CR18","doi-asserted-by":"crossref","first-page":"789788","DOI":"10.3389\/fimmu.2021.789788","volume":"12","author":"AS Clottu","year":"2021","unstructured":"Clottu AS, et al. Innate lymphoid cells in autoimmune diseases. Front Immunol. 2021;12:789788.","journal-title":"Front Immunol"},{"issue":"5","key":"2126_CR19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1042\/CS20130367","volume":"126","author":"S O'Reilly","year":"2014","unstructured":"O\u2019Reilly S. Innate immunity in systemic sclerosis pathogenesis. Clin Sci. 2014;126(5):329\u201337.","journal-title":"Clin Sci"},{"key":"2126_CR20","doi-asserted-by":"crossref","first-page":"999008","DOI":"10.3389\/fimmu.2022.999008","volume":"13","author":"CF Beesley","year":"2022","unstructured":"Beesley CF, et al. Dysregulated B cell function and disease pathogenesis in systemic sclerosis. Front Immunol. 2022;13:999008.","journal-title":"Front Immunol"},{"key":"2126_CR21","doi-asserted-by":"crossref","first-page":"933468","DOI":"10.3389\/fimmu.2022.933468","volume":"13","author":"B Thoreau","year":"2022","unstructured":"Thoreau B, Chaigne B, Mouthon L. Role of B-cell in the pathogenesis of systemic sclerosis. Front Immunol. 2022;13:933468.","journal-title":"Front Immunol"},{"key":"2126_CR22","doi-asserted-by":"crossref","first-page":"156534","DOI":"10.1016\/j.cyto.2024.156534","volume":"176","author":"N Seki","year":"2024","unstructured":"Seki N, et al. Th17\/IL-17A axis is critical for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc): SSc patients with high levels of serum IL-17A exhibit reduced lung functions and increased prevalence of PAH. Cytokine. 2024;176:156534.","journal-title":"Cytokine"},{"issue":"1","key":"2126_CR23","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/ar4430","volume":"16","author":"X Yang","year":"2014","unstructured":"Yang X, et al. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther. 2014;16(1):R4.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2126_CR24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10238-023-01286-9","volume":"24","author":"M Sahinoglu","year":"2024","unstructured":"Sahinoglu M, et al. The relationship between peripheral T follicular helper cells and disease severity in systemic sclerosis. Clin Exp Med. 2024;24(1):19.","journal-title":"Clin Exp Med"},{"issue":"1","key":"2126_CR25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12967-021-03049-0","volume":"19","author":"P Beurier","year":"2021","unstructured":"Beurier P, et al. Tfh cells in systemic sclerosis. J Transl Med. 2021;19(1):375.","journal-title":"J Transl Med"},{"key":"2126_CR26","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.2147\/JIR.S379815","volume":"16","author":"M Muruganandam","year":"2023","unstructured":"Muruganandam M, et al. Biomarkers in the pathogenesis, diagnosis, and treatment of systemic sclerosis. J Inflamm Res. 2023;16:4633\u201360.","journal-title":"J Inflamm Res"},{"issue":"9","key":"2126_CR27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly S, H\u00fcgle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. 2012;51(9):1540\u20139.","journal-title":"Rheumatology"},{"issue":"1","key":"2126_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1081-1206(10)62426-X","volume":"85","author":"S Romagnani","year":"2000","unstructured":"Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol. 2000;85(1):9\u201318.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"2126_CR29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/ar2598","volume":"11","author":"C Beyer","year":"2009","unstructured":"Beyer C, et al. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther. 2009;11(2):220.","journal-title":"Arthritis Res Ther"},{"key":"2126_CR30","doi-asserted-by":"crossref","first-page":"929289","DOI":"10.3389\/fimmu.2022.929289","volume":"13","author":"X He","year":"2022","unstructured":"He X, et al. Intimate intertwining of the pathogenesis of hypoxia and systemic sclerosis: a transcriptome integration analysis. Front Immunol. 2022;13:929289.","journal-title":"Front Immunol"},{"issue":"7","key":"2126_CR31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tcm.2012.05.011","volume":"21","author":"M Manetti","year":"2011","unstructured":"Manetti M, et al. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med. 2011;21(7):204\u201310.","journal-title":"Trends Cardiovasc Med"},{"issue":"3","key":"2126_CR32","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/CIRCRESAHA.111.242057","volume":"109","author":"M Manetti","year":"2011","unstructured":"Manetti M, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res. 2011;109(3):e14-26.","journal-title":"Circ Res"},{"issue":"4","key":"2126_CR33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaad.2022.10.001","volume":"88","author":"M Motamedi","year":"2023","unstructured":"Motamedi M, et al. Skin disorders and interstitial lung disease: part I-screening, diagnosis, and therapeutic principles. J Am Acad Dermatol. 2023;88(4):751\u201364.","journal-title":"J Am Acad Dermatol"},{"key":"2126_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051310","author":"A Bohdziewicz","year":"2022","unstructured":"Bohdziewicz A, et al. Future treatment options in systemic sclerosis-potential targets and ongoing clinical trials. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11051310.","journal-title":"J Clin Med"},{"issue":"1","key":"2126_CR35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-022-02787-w","volume":"24","author":"M Rokni","year":"2022","unstructured":"Rokni M, et al. The role of endothelin and RAS\/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications. Arthritis Res Ther. 2022;24(1):108.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2126_CR36","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","volume":"59","author":"B Yaseen","year":"2020","unstructured":"Yaseen B, et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology. 2020;59(9):2625\u201336.","journal-title":"Rheumatology"},{"issue":"7","key":"2126_CR37","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s13555-023-00952-w","volume":"13","author":"M Maciejewska","year":"2023","unstructured":"Maciejewska M, et al. Hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) as a biomarker for changes in microcirculation in individuals with systemic sclerosis. Dermatol Ther. 2023;13(7):1549\u201360.","journal-title":"Dermatol Ther"},{"key":"2126_CR38","doi-asserted-by":"crossref","first-page":"788250","DOI":"10.3389\/fmed.2021.788250","volume":"8","author":"DC Zanin-Silva","year":"2021","unstructured":"Zanin-Silva DC, et al. Management of endothelial dysfunction in systemic sclerosis: current and developing strategies. Front Med Lausanne. 2021;8:788250.","journal-title":"Front Med Lausanne"},{"key":"2126_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101471","author":"I Szabo","year":"2021","unstructured":"Szabo I, et al. Novel concepts in systemic sclerosis pathogenesis: role for miRNAs. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9101471.","journal-title":"Biomedicines"},{"issue":"6","key":"2126_CR40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","volume":"9","author":"M Osaki","year":"2004","unstructured":"Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9(6):667\u201376.","journal-title":"Apoptosis"},{"issue":"1","key":"2126_CR41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1582-4934.2005.tb00337.x","volume":"9","author":"G Song","year":"2005","unstructured":"Song G, Ouyang G, Bao S. The activation of Akt\/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9(1):59\u201371.","journal-title":"J Cell Mol Med"},{"issue":"9","key":"2126_CR42","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/febs.16297","volume":"289","author":"R Mohamed","year":"2022","unstructured":"Mohamed R, et al. Akt acts as a switch for GPCR transactivation of the TGF-\u03b2 receptor type 1. FEBS J. 2022;289(9):2642\u201356.","journal-title":"FEBS J"},{"issue":"8","key":"2126_CR43","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.7150\/ijbs.77649","volume":"19","author":"Y Huang","year":"2023","unstructured":"Huang Y, et al. Enhancement of Zyxin promotes skin fibrosis by regulating FAK\/PI3K\/AKT and TGF-\u03b2 signaling pathways via integrins. Int J Biol Sci. 2023;19(8):2394\u2013408.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2126_CR44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, et al. Targeting PI3K\/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm Sin B. 2022;12(1):18\u201332.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"2126_CR45","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1038\/s41598-023-41927-3","volume":"13","author":"Q Nie","year":"2023","unstructured":"Nie Q, et al. PI3K\/Akt signalling pathway-associated long noncoding RNA signature predicts the prognosis of laryngeal cancer patients. Sci Rep. 2023;13(1):14764.","journal-title":"Sci Rep"},{"key":"2126_CR46","doi-asserted-by":"crossref","first-page":"890109","DOI":"10.3389\/fped.2022.890109","volume":"10","author":"N Wang","year":"2022","unstructured":"Wang N, et al. Regulation of COL1A2, AKT3 genes, and related signaling pathway in the pathology of congenital talipes equinovarus. Front Pediatr. 2022;10:890109.","journal-title":"Front Pediatr"},{"key":"2126_CR47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.biochi.2019.08.003","volume":"165","author":"M Karimi Roshan","year":"2019","unstructured":"Karimi Roshan M, et al. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie. 2019;165:229\u201334.","journal-title":"Biochimie"},{"issue":"2","key":"2126_CR48","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","volume":"19","author":"J Xu","year":"2009","unstructured":"Xu J, Lamouille S, Derynck R. TGF-\u03b2-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156\u201372.","journal-title":"Cell Res"},{"issue":"1","key":"2126_CR49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-018-07858-8","volume":"10","author":"HV Woodcock","year":"2019","unstructured":"Woodcock HV, et al. The mTORC1\/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nat Commun. 2019;10(1):6.","journal-title":"Nat Commun"},{"key":"2126_CR50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semcdb.2019.11.013","volume":"101","author":"KW Finnson","year":"2020","unstructured":"Finnson KW, Almadani Y, Philip A. Non-canonical (non-SMAD2\/3) TGF-\u03b2 signaling in fibrosis: mechanisms and targets. Semin Cell Dev Biol. 2020;101:115\u201322.","journal-title":"Semin Cell Dev Biol"},{"key":"2126_CR51","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0269-2020","author":"M Plat\u00e9","year":"2020","unstructured":"Plat\u00e9 M, Guillotin D, Chambers RC. The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis. Eur Respir Rev. 2020. https:\/\/doi.org\/10.1183\/16000617.0269-2020.","journal-title":"Eur Respir Rev"},{"issue":"4","key":"2126_CR52","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.joca.2020.02.027","volume":"28","author":"K Sun","year":"2020","unstructured":"Sun K, et al. The PI3K\/AKT\/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthr Cartil. 2020;28(4):400\u20139.","journal-title":"Osteoarthr Cartil"},{"issue":"4","key":"2126_CR53","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/ncb1117","volume":"6","author":"AR Conery","year":"2004","unstructured":"Conery AR, et al. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-\u03b2-induced apoptosis. Nat Cell Biol. 2004;6(4):366\u201372.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"2126_CR54","doi-asserted-by":"crossref","first-page":"H2211","DOI":"10.1152\/ajpheart.00966.2011","volume":"302","author":"PA Suwanabol","year":"2012","unstructured":"Suwanabol PA, et al. TGF-\u03b2 and Smad3 modulate PI3K\/Akt signaling pathway in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2012;302(11):H2211\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2126_CR55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-00435-w","volume":"6","author":"D Yang","year":"2021","unstructured":"Yang D, et al. G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduct Target Ther. 2021;6(1):7.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2126_CR56","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.3390\/ijms18122519","volume":"18","author":"VV Gurevich","year":"2017","unstructured":"Gurevich VV, Gurevich EV. Molecular mechanisms of GPCR signaling: a structural perspective. Int J Mol Sci. 2017;18(12):2519.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"2126_CR57","doi-asserted-by":"crossref","first-page":"e2110085119","DOI":"10.1073\/pnas.2110085119","volume":"119","author":"A Mafi","year":"2022","unstructured":"Mafi A, Kim S-K, Goddard WA III. The mechanism for ligand activation of the GPCR\u2013G protein complex. Proc Natl Acad Sci USA. 2022;119(18):e2110085119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2126_CR58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0625.2010.01184.x","volume":"20","author":"F Cevikbas","year":"2011","unstructured":"Cevikbas F, et al. Role of protease-activated receptors in human skin fibrosis and scleroderma. Exp Dermatol. 2011;20(1):69\u201371.","journal-title":"Exp Dermatol"},{"issue":"44","key":"2126_CR59","doi-asserted-by":"crossref","first-page":"29888","DOI":"10.1074\/jbc.M803880200","volume":"283","author":"J Gavard","year":"2008","unstructured":"Gavard J, Gutkind JS. Protein kinase C-related kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from G\u03b112\/13 and G\u03b111\/q. J Biol Chem. 2008;283(44):29888\u201396.","journal-title":"J Biol Chem"},{"issue":"Suppl 131","key":"2126_CR60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.55563\/clinexprheumatol\/d03dnc","volume":"39","author":"P Kuszmiersz","year":"2021","unstructured":"Kuszmiersz P, et al. Thrombin generation potential is enhanced in systemic sclerosis: impact of selected endothelial biomarkers. Clin Exp Rheumatol. 2021;39(Suppl 131):13\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"2126_CR61","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1007\/s10238-023-01222-x","volume":"23","author":"F Marongiu","year":"2023","unstructured":"Marongiu F, et al. A journey to vasculopathy in systemic sclerosis: focus on haemostasis and thrombosis. Clin Exp Med. 2023;23(8):4057\u201364.","journal-title":"Clin Exp Med"},{"key":"2126_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123358","author":"CQ Chu","year":"2024","unstructured":"Chu CQ, Quan T. Fibroblast Yap\/Taz signaling in extracellular matrix homeostasis and tissue fibrosis. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13123358.","journal-title":"J Clin Med"},{"issue":"3","key":"2126_CR63","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tips.2019.12.008","volume":"41","author":"AJ Haak","year":"2020","unstructured":"Haak AJ, et al. Targeting GPCR signaling for idiopathic pulmonary fibrosis therapies. Trends Pharmacol Sci. 2020;41(3):172\u201382.","journal-title":"Trends Pharmacol Sci"},{"key":"2126_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042299","author":"M Binda","year":"2024","unstructured":"Binda M, et al. Autoantibodies targeting G-protein-coupled receptors: pathogenetic, clinical and therapeutic implications in systemic sclerosis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25042299.","journal-title":"Int J Mol Sci"},{"key":"2126_CR65","doi-asserted-by":"crossref","first-page":"106754","DOI":"10.1016\/j.phrs.2023.106754","volume":"191","author":"Z Ren","year":"2023","unstructured":"Ren Z, et al. G protein coupled receptor 41 regulates fibroblast activation in pulmonary fibrosis via G\u03b1(i\/o) and downstream Smad2\/3 and ERK1\/2 phosphorylation. Pharmacol Res. 2023;191:106754.","journal-title":"Pharmacol Res"},{"key":"2126_CR66","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12295","author":"N Asokananthan","year":"2015","unstructured":"Asokananthan N, et al. Activation of protease-activated receptors (PARs)-1 and -2 promotes alpha-smooth muscle actin expression and release of cytokines from human lung fibroblasts. Physiol Rep. 2015. https:\/\/doi.org\/10.14814\/phy2.12295.","journal-title":"Physiol Rep"},{"issue":"3","key":"2126_CR67","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12016-022-08945-x","volume":"64","author":"A Cole","year":"2023","unstructured":"Cole A, Ong VH, Denton CP. Renal disease and systemic sclerosis: an update on scleroderma renal crisis. Clin Rev Allergy Immunol. 2023;64(3):378\u201391.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2126_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020927","author":"G Civieri","year":"2022","unstructured":"Civieri G, Iop L, Tona F. Antibodies against angiotensin II type 1 and endothelin 1 type A receptors in cardiovascular pathologies. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23020927.","journal-title":"Int J Mol Sci"},{"key":"2126_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13223398","author":"MA Maranduca","year":"2023","unstructured":"Maranduca MA, et al. The renin-angiotensin system: the challenge behind autoimmune dermatological diseases. Diagnostics. 2023. https:\/\/doi.org\/10.3390\/diagnostics13223398.","journal-title":"Diagnostics"},{"issue":"1","key":"2126_CR70","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar4457","volume":"16","author":"A Kill","year":"2014","unstructured":"Kill A, et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther. 2014;16(1):R29.","journal-title":"Arthritis Res Ther"},{"key":"2126_CR71","doi-asserted-by":"crossref","first-page":"1231875","DOI":"10.3389\/fonc.2023.1231875","volume":"13","author":"YN Wu","year":"2023","unstructured":"Wu YN, et al. The roles of phospholipase C-\u03b2 related signals in the proliferation, metastasis and angiogenesis of malignant tumors, and the corresponding protective measures. Front Oncol. 2023;13:1231875.","journal-title":"Front Oncol"},{"key":"2126_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054475","author":"R Duangrat","year":"2023","unstructured":"Duangrat R, et al. Endothelin-1 induces cell proliferation and myofibroblast differentiation through the ET(A)R\/G(\u03b1q)\/ERK signaling pathway in human cardiac fibroblasts. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24054475.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2126_CR73","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-018-1545-8","volume":"20","author":"F Weigold","year":"2018","unstructured":"Weigold F, et al. Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. Arthritis Res Ther. 2018;20(1):52.","journal-title":"Arthritis Res Ther"},{"key":"2126_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061331","author":"E Romano","year":"2024","unstructured":"Romano E, et al. Recent insights into cellular and molecular mechanisms of defective angiogenesis in systemic sclerosis. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12061331.","journal-title":"Biomedicines"},{"issue":"11","key":"2126_CR75","doi-asserted-by":"crossref","first-page":"G1052","DOI":"10.1152\/ajpgi.00034.2016","volume":"310","author":"S Kumar","year":"2016","unstructured":"Kumar S, et al. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1052\u201360.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2126_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126663","author":"F Centeno","year":"2024","unstructured":"Centeno F. Editorial for the special issue \u201cMAPK in Health and Disease.\u201d Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25126663.","journal-title":"Int J Mol Sci"},{"issue":"28","key":"2126_CR77","doi-asserted-by":"crossref","first-page":"e2404887121","DOI":"10.1073\/pnas.2404887121","volume":"121","author":"M Otani","year":"2024","unstructured":"Otani M, et al. The MKK3 MAPK cascade integrates temperature and after-ripening signals to modulate seed germination. Proc Natl Acad Sci USA. 2024;121(28):e2404887121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2126_CR78","doi-asserted-by":"crossref","first-page":"154821","DOI":"10.1016\/j.phymed.2023.154821","volume":"115","author":"MM Gravandi","year":"2023","unstructured":"Gravandi MM, et al. Therapeutic targeting of Ras\/Raf\/MAPK pathway by natural products: a systematic and mechanistic approach for neurodegeneration. Phytomedicine. 2023;115:154821.","journal-title":"Phytomedicine"},{"issue":"2","key":"2126_CR79","first-page":"197","volume":"23","author":"M Rokni","year":"2024","unstructured":"Rokni M, et al. Interferon-\u03b3 induces interleukin-6 production and alpha-smooth muscle actin expression in systemic sclerosis fibroblasts. Iran J Allergy Asthma Immunol. 2024;23(2):197\u2013220.","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"1","key":"2126_CR80","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1755-1536-4-8","volume":"4","author":"S Smaldone","year":"2011","unstructured":"Smaldone S, et al. Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts. Fibrogenesis Tissue Repair. 2011;4(1):8.","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"5","key":"2126_CR81","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/art.33501","volume":"64","author":"J Avouac","year":"2012","unstructured":"Avouac J, et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor \u03b2-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 2012;64(5):1642\u201352.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2126_CR82","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/art.38897","volume":"67","author":"M Ponticos","year":"2015","unstructured":"Ponticos M, et al. Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. Arthritis Rheumatol. 2015;67(1):243\u201353.","journal-title":"Arthritis Rheumatol"},{"key":"2126_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111793","author":"M Simon","year":"2021","unstructured":"Simon M, et al. Autoantibodies from patients with scleroderma renal crisis promote PAR-1 receptor activation and IL-6 production in endothelial cells. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222111793.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2126_CR84","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.4049\/jimmunol.1201115","volume":"189","author":"CG Lee","year":"2012","unstructured":"Lee CG, et al. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-\u03b21 signaling. J Immunol. 2012;189(5):2635\u201344.","journal-title":"J Immunol"},{"issue":"2","key":"2126_CR85","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.23146","volume":"58","author":"Y Chen","year":"2008","unstructured":"Chen Y, et al. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. Arthritis Rheum. 2008;58(2):577\u201385.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2126_CR86","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1093\/rheumatology\/keab168","volume":"60","author":"E Adami","year":"2021","unstructured":"Adami E, et al. IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGF\u03b2-mediated activation of dermal fibroblasts. Rheumatology. 2021;60(12):5820\u20136.","journal-title":"Rheumatology"},{"issue":"6","key":"2126_CR87","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1186\/s13075-014-0512-2","volume":"16","author":"M Liu","year":"2014","unstructured":"Liu M, et al. Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway. Arthritis Res Ther. 2014;16(6):4223.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2126_CR88","doi-asserted-by":"crossref","first-page":"e85032","DOI":"10.1371\/journal.pone.0085032","volume":"8","author":"X Xing","year":"2013","unstructured":"Xing X, et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS ONE. 2013;8(12):e85032.","journal-title":"PLoS ONE"},{"issue":"2","key":"2126_CR89","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.0022-202X.2005.23766.x","volume":"125","author":"H Ihn","year":"2005","unstructured":"Ihn H, Yamane K, Tamaki K. Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J Invest Dermatol. 2005;125(2):247\u201355.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"2126_CR90","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees C, et al. Jak-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheum. 2012;64(9):3006\u201315.","journal-title":"Arthritis Rheum"},{"key":"2126_CR91","doi-asserted-by":"crossref","first-page":"107217","DOI":"10.1016\/j.phrs.2024.107217","volume":"204","author":"Y Lv","year":"2024","unstructured":"Lv Y, et al. Small molecule drug discovery targeting the JAK-STAT pathway. Pharmacol Res. 2024;204:107217.","journal-title":"Pharmacol Res"},{"key":"2126_CR92","doi-asserted-by":"crossref","first-page":"859330","DOI":"10.3389\/fmed.2022.859330","volume":"9","author":"Z Hou","year":"2022","unstructured":"Hou Z, et al. JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis. Front Med. 2022;9:859330.","journal-title":"Front Med"},{"issue":"10","key":"2126_CR93","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s10067-023-06660-2","volume":"42","author":"Z Junfei","year":"2023","unstructured":"Junfei Z, et al. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2023;42(10):2823\u201332.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"2126_CR94","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/14712598.2023.2196009","volume":"23","author":"E Mulcaire-Jones","year":"2023","unstructured":"Mulcaire-Jones E, et al. Advances in biological and targeted therapies for systemic sclerosis. Expert Opin Biol Ther. 2023;23(4):325\u201339.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2126_CR95","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2126_CR96","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/cia2.12288","volume":"6","author":"WW Aung","year":"2023","unstructured":"Aung WW, Hamaguchi Y, Matsushita T. Targeting cytokines and potentiality of JAK\u2013STAT inhibition in systemic sclerosis. J Cutan Immunol Allergy. 2023;6(1):4\u201312.","journal-title":"J Cutan Immunol Allergy"},{"issue":"5\u20136","key":"2126_CR97","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","volume":"19","author":"Q Zhang","year":"2008","unstructured":"Zhang Q, et al. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19(5\u20136):347\u201356.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2126_CR98","doi-asserted-by":"crossref","first-page":"109723","DOI":"10.1016\/j.intimp.2023.109723","volume":"116","author":"N Bellamri","year":"2023","unstructured":"Bellamri N, et al. Effects of ruxolitinib on fibrosis in preclinical models of systemic sclerosis. Int Immunopharmacol. 2023;116:109723.","journal-title":"Int Immunopharmacol"},{"key":"2126_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/life12122101","author":"E Fiorentini","year":"2022","unstructured":"Fiorentini E, et al. Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data. Life. 2022. https:\/\/doi.org\/10.3390\/life12122101.","journal-title":"Life"},{"key":"2126_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/ph15080936","author":"P Kotyla","year":"2022","unstructured":"Kotyla P, et al. Jak inhibitors for treatment of autoimmune diseases: lessons from Systemic Sclerosis and Systemic Lupus Erythematosus. Pharmaceuticals. 2022. https:\/\/doi.org\/10.3390\/ph15080936.","journal-title":"Pharmaceuticals"},{"issue":"4","key":"2126_CR101","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40674-021-00188-9","volume":"7","author":"M Wu","year":"2021","unstructured":"Wu M, Assassi S. Dysregulation of type 1 interferon signaling in systemic sclerosis: a promising therapeutic target? Curr Treat Options Rheumatol. 2021;7(4):349\u201360.","journal-title":"Curr Treat Options Rheumatol"},{"issue":"2","key":"2126_CR102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/labinvest.2015.154","volume":"96","author":"C Bergmann","year":"2016","unstructured":"Bergmann C, Distler JHW. Canonical wnt signaling in systemic sclerosis. Lab Invest. 2016;96(2):151\u20135.","journal-title":"Lab Invest"},{"issue":"8","key":"2126_CR103","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2020-219822","volume":"80","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, et al. X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc). Ann Rheum Dis. 2021;80(8):1048\u201356.","journal-title":"Ann Rheum Dis"},{"key":"2126_CR104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2019.02.010","volume":"209","author":"B Korman","year":"2019","unstructured":"Korman B. Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis. Transl Res. 2019;209:77\u201389.","journal-title":"Transl Res"},{"key":"2126_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093069","author":"CY Tsai","year":"2020","unstructured":"Tsai CY, et al. Pathogenic roles of autoantibodies and aberrant epigenetic regulation of immune and connective tissue cells in the tissue fibrosis of patients with systemic sclerosis. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21093069.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2126_CR106","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40437","volume":"70","author":"J Gillespie","year":"2018","unstructured":"Gillespie J, et al. Transforming growth factor \u03b2 activation primes canonical Wnt signaling through down-regulation of Axin-2. Arthritis Rheumatol. 2018;70(6):932\u201342.","journal-title":"Arthritis Rheumatol"},{"key":"2126_CR107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cellsig.2018.01.019","volume":"45","author":"NM Pawar","year":"2018","unstructured":"Pawar NM, Rao P. Secreted frizzled related protein 4 (sFRP4) update: a brief review. Cell Signal. 2018;45:63\u201370.","journal-title":"Cell Signal"},{"key":"2126_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245820","author":"I Tinazzi","year":"2021","unstructured":"Tinazzi I, et al. Sfrp4 expression is linked to immune-driven fibrotic conditions, correlates with skin and lung fibrosis in SSc and a potential EMT biomarker. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10245820.","journal-title":"J Clin Med"},{"key":"2126_CR109","doi-asserted-by":"crossref","first-page":"tkac011","DOI":"10.1093\/burnst\/tkac011","volume":"10","author":"L Liu","year":"2022","unstructured":"Liu L, et al. Epithelial-mesenchymal transition in organ fibrosis development: current understanding and treatment strategies. Burns Trauma. 2022;10:tkac011.","journal-title":"Burns Trauma"},{"issue":"3","key":"2126_CR110","doi-asserted-by":"crossref","first-page":"341","DOI":"10.18388\/abp.2018_2635","volume":"65","author":"E Dzia\u0142o","year":"2018","unstructured":"Dzia\u0142o E, Tkacz K, B\u0142yszczuk P. Crosstalk between the TGF-\u03b2 and WNT signalling pathways during cardiac fibrogenesis. Acta Biochim Pol. 2018;65(3):341\u20139.","journal-title":"Acta Biochim Pol"},{"issue":"7","key":"2126_CR111","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/15592294.2020.1827715","volume":"16","author":"J Henderson","year":"2021","unstructured":"Henderson J, et al. Microrna27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosis. Epigenetics. 2021;16(7):808\u201317.","journal-title":"Epigenetics"},{"issue":"18","key":"2126_CR112","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1111\/bph.15190","volume":"177","author":"L Ledein","year":"2020","unstructured":"Ledein L, et al. Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. Br J Pharmacol. 2020;177(18):4296\u2013309.","journal-title":"Br J Pharmacol"},{"key":"2126_CR113","first-page":"45","volume":"36","author":"D Daoussis","year":"2018","unstructured":"Daoussis D, et al. Dickkopf-1 is downregulated early and universally in the skin of patients with systemic sclerosis despite normal circulating levels. Clin Exp Rheumatol. 2018;36:45\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"2126_CR114","doi-asserted-by":"crossref","first-page":"174","DOI":"10.31138\/mjr.28.4.174","volume":"28","author":"K Klavdianou","year":"2017","unstructured":"Klavdianou K, Liossis SN, Daoussis D. Dkk1: a key molecule in joint remodelling and fibrosis. Mediterr J Rheumatol. 2017;28(4):174\u201382.","journal-title":"Mediterr J Rheumatol"},{"issue":"4","key":"2126_CR115","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.semarthrit.2016.08.014","volume":"46","author":"K Klavdianou","year":"2017","unstructured":"Klavdianou K, et al. The role of Dickkopf-1 in joint remodeling and fibrosis: a link connecting spondyloarthropathies and scleroderma? Semin Arthritis Rheum. 2017;46(4):430\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"2126_CR116","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13020-018-0175-z","volume":"13","author":"Q Wang","year":"2018","unstructured":"Wang Q, et al. Wenyang huazhuo tongluo formula inhibits fibrosis via suppressing Wnt\/\u03b2-catenin signaling pathway in a bleomycin-induced systemic sclerosis mouse model. Chin Med. 2018;13:17.","journal-title":"Chin Med"},{"issue":"12","key":"2126_CR117","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.jid.2022.03.038","volume":"142","author":"X Heim","year":"2022","unstructured":"Heim X, et al. CD146 at the interface between oxidative stress and the Wnt signaling pathway in systemic sclerosis. J Invest Dermatol. 2022;142(12):3200-3210.e5.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2126_CR118","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00018-015-2076-y","volume":"73","author":"K Kumawat","year":"2016","unstructured":"Kumawat K, Gosens R. WNT-5A: signaling and functions in health and disease. Cell Mol Life Sci. 2016;73(3):567\u201387.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2126_CR119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/etm.2014.1676","volume":"8","author":"N Zhu","year":"2014","unstructured":"Zhu N, et al. Challenging role of Wnt5a and its signaling pathway in cancer metastasis (review). Exp Ther Med. 2014;8(1):3\u20138.","journal-title":"Exp Ther Med"},{"issue":"9","key":"2126_CR120","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2014-09-598540","volume":"126","author":"Z Kabiri","year":"2015","unstructured":"Kabiri Z, et al. Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells. Blood. 2015;126(9):1086\u201394.","journal-title":"Blood"},{"issue":"5","key":"2126_CR121","doi-asserted-by":"crossref","first-page":"101047","DOI":"10.1016\/j.isci.2020.101047","volume":"23","author":"XJ Tian","year":"2020","unstructured":"Tian XJ, et al. Sequential wnt agonist then antagonist treatment accelerates tissue repair and minimizes fibrosis. iScience. 2020;23(5):101047.","journal-title":"iScience"},{"issue":"8","key":"2126_CR122","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","volume":"64","author":"J Wei","year":"2012","unstructured":"Wei J, et al. Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012;64(8):2734\u201345.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2126_CR123","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12929-021-00732-8","volume":"28","author":"AG Condorelli","year":"2021","unstructured":"Condorelli AG, et al. Notch-ing up knowledge on molecular mechanisms of skin fibrosis: focus on the multifaceted Notch signalling pathway. J Biomed Sci. 2021;28(1):36.","journal-title":"J Biomed Sci"},{"issue":"8","key":"2126_CR124","first-page":"1618","volume":"41","author":"K Li","year":"2023","unstructured":"Li K, et al. Exploration and validation of the hub genes involved in hypoxia-induced endothelial-mesenchymal transition of systemic sclerosis. Clin Exp Rheumatol. 2023;41(8):1618\u201331.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"2126_CR125","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/1744666X.2021.2000391","volume":"17","author":"F Seguro Paula","year":"2021","unstructured":"Seguro Paula F, Delgado Alves J. The role of the Notch pathway in the pathogenesis of systemic sclerosis: clinical implications. Expert Rev Clin Immunol. 2021;17(12):1257\u201367.","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"2126_CR126","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jid.2024.03.024","volume":"144","author":"CW Wasson","year":"2024","unstructured":"Wasson CW, et al. The beta secretase BACE1 drives fibroblasts activation in systemic sclerosis through the APP\/\u03b2-catenin\/Notch signalling axis. J Invest Dermatol. 2024;144(10):2197\u2013210.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2126_CR127","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5021\/ad.2019.31.4.365","volume":"31","author":"S Zmorzy\u0144ski","year":"2019","unstructured":"Zmorzy\u0144ski S, et al. The significance of NOTCH pathway in the development of fibrosis in systemic sclerosis. Ann Dermatol. 2019;31(4):365\u201371.","journal-title":"Ann Dermatol"},{"key":"2126_CR128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.phrs.2016.04.010","volume":"108","author":"B Hu","year":"2016","unstructured":"Hu B, Phan SH. Notch in fibrosis and as a target of anti-fibrotic therapy. Pharmacol Res. 2016;108:57\u201364.","journal-title":"Pharmacol Res"},{"key":"2126_CR129","doi-asserted-by":"crossref","first-page":"1450038","DOI":"10.3389\/fcell.2024.1450038","volume":"12","author":"X Zhang","year":"2024","unstructured":"Zhang X, et al. Notch signaling regulates pulmonary fibrosis. Front Cell Dev Biol. 2024;12:1450038.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"2126_CR130","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard.2010.134742","volume":"70","author":"C Dees","year":"2011","unstructured":"Dees C, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis. 2011;70(7):1304\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2126_CR131","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/annrheumdis-2013-204221","volume":"73","author":"A Distler","year":"2014","unstructured":"Distler A, et al. Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann Rheum Dis. 2014;73(6):1264\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2126_CR132","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1874312901206010096","volume":"6","author":"N Kavian","year":"2012","unstructured":"Kavian N, et al. New insights into the mechanism of notch signalling in fibrosis. Open Rheumatol J. 2012;6:96\u2013102.","journal-title":"Open Rheumatol J"},{"issue":"2","key":"2126_CR133","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.18632\/aging.202308","volume":"13","author":"Q Yao","year":"2020","unstructured":"Yao Q, et al. Mir-16-5p suppresses myofibroblast activation in systemic sclerosis by inhibiting NOTCH signaling. Aging. 2020;13(2):2640\u201354.","journal-title":"Aging"},{"issue":"1","key":"2126_CR134","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-020-02376-9","volume":"22","author":"CW Wasson","year":"2020","unstructured":"Wasson CW, et al. Long non-coding RNA HOTAIR induces GLI2 expression through Notch signalling in systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2020;22(1):286.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2126_CR135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/annrheumdis-2019-216542","volume":"79","author":"CW Wasson","year":"2020","unstructured":"Wasson CW, et al. Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Ann Rheum Dis. 2020;79(4):507\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2126_CR136","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jid.2018.08.021","volume":"139","author":"S Harrach","year":"2019","unstructured":"Harrach S, et al. Notch signaling activity determines uptake and biological effect of imatinib in systemic sclerosis dermal fibroblasts. J Invest Dermatol. 2019;139(2):439\u201347.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2126_CR137","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1002\/art.27626","volume":"62","author":"N Kavian","year":"2010","unstructured":"Kavian N, et al. Targeting ADAM-17\/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010;62(11):3477\u201387.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2126_CR138","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/stem.408","volume":"28","author":"L Borghese","year":"2010","unstructured":"Borghese L, et al. Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1\/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells. 2010;28(5):955\u201364.","journal-title":"Stem Cells"},{"issue":"5","key":"2126_CR139","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/art.30254","volume":"63","author":"C Dees","year":"2011","unstructured":"Dees C, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum. 2011;63(5):1396\u2013404.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2126_CR140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/stem.254","volume":"28","author":"X Fan","year":"2010","unstructured":"Fan X, et al. Notch pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells. 2010;28(1):5\u201316.","journal-title":"Stem Cells"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02126-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:54:17Z","timestamp":1767200057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02126-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2126"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02126-0","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"158"}}